Creative Planning
TXG icon

Creative Planning’s 10x Genomics TXG Stock Holding History

Creative Planning’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Buy
106,351
+15,040
+16% +$394K ﹤0.01% 1558
2026
Q1 		$1.94M Buy
91,311
+32,592
+56% +$652K ﹤0.01% 1910
2025
Q4 		$958K Buy
58,719
+1,845
+3% +$27.9K ﹤0.01% 2319
2025
Q3 		$665K Buy
56,874
+1,637
+3% +$21.3K ﹤0.01% 2474
2025
Q2 		$640K Buy
55,237
+25,252
+84% +$230K ﹤0.01% 2249
2025
Q1 		$262K Buy
29,985
+17,075
+132% +$215K ﹤0.01% 2869
2024
Q4 		$185K Buy
12,910
+3,420
+36% +$54K ﹤0.01% 2995
2024
Q3 		$214K Buy
+9,490
New +$196K ﹤0.01% 2780

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Creative Planning's TXG Position: Q2 2026 in Review

Creative Planning increased its 10x Genomics (TXG) stake by 16% in Q2 2026, buying an estimated $394K and bringing the position to 106,351 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1558.

Creative Planning first reported a position in TXG in Q3 2024 and has held it in 8 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Creative Planning held 106,351 shares of 10x Genomics worth $4.08M as of Q2 2026.
  • Creative Planning bought 15,040 10x Genomics shares in Q2 2026, an estimated $394K.
  • 10x Genomics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1558 holding.
  • Creative Planning first reported a position in 10x Genomics in Q3 2024 and has held it in 8 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.